INTRODUCTION
http://dx.doi.org/10.4062/biomolther.2015.021 13-AMP), (Fig 1) ], a structural analog of KTH-13, and then examined its anti-cancer activity by analyzing its ability to inhibit proliferation, and checked the pro-apoptosis mechanism in various cancer cells.
MATERIALS AND METHODS

Materials
4-isopropyl-2-(1-phenylethyl) aniline [KTH-13-amine-monophenyl (KTH-13-AMP)] was supplied by Prof Lee, Yunmi (Kwangwoon University, Seoul) . The purity of this compound was more than 98% according to HPLC analysis. (3-4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, tetrazole (MTT) was purchased from Sigma Chemical Co. (St. Louis, MO, USA). Fetal bovine serum (FBS), Dulbecco's modifi ed Eagle's medium (DMEM) and penicillin/streptomycin were obtained from Thermo Fisher Scientifi c Inc. (Waltham, MA, USA). C6 glioma cells, human breast cancer MDA-MB-231 cells, and a human cervical adenocarcinoma (HeLa) cell line were purchased from ATCC (Rockville, MD, USA). A FITC Annexin V Apoptosis Detection Kit I was obtained from BD biosciences (San Diego, CA, USA). Phospho-specifi c and total antibodies against caspases (3, 8, and 9), Bax, Bcl-2, STAT3, PI3K/p85, Src, and β-actin were obtained from Cell Signaling (Beverly, MA, USA).
Cell culture
C6 glioma cells, MDA-MB-231, and HeLa cells were cultured in DMEM with 5% heat-inactivated FBS and 1% penicillin/streptomycin at 37 o C in 5% CO 2 . For each experiment, cells were detached with trypsin/EDTA solution. The cell density used in our experiments was 5×10 5 cells/ml.
Cell viability test
After pre-incubation of C6 glioma, MDA-MB-231, and HeLa cells (5×10 5 cells/ml) for 18 h, the testing compound was applied to the cells dose-dependently and incubated for 6 h or 24 h under 5% FBS conditions. The effect of KTH-13-AMP on proliferation was then evaluated using a conventional MTT assay (Kim and Cho, 2013a; Twentyman and Luscombe 1987) . Ten microliters of MTT solution (10 mg/ml in phosphate-buffered saline (PBS), pH 7.4) was added to the cultures, and the cells were incubated for 3-4 hours. The incubation was stopped by the addition of 15% sodium dodecyl sulphate to each well to solubilize the formazan (Kim and Cho, 2013a) . The absorbance at 570 nm (OD 570-630 ) was assessed using a Spectramax 250 microplate reader.
Morphological change test
KTH-13-AMP-treated C6 glioma cells were incubated with the indicated doses for the indicated times. Images of the cells in culture at each time point were obtained using an inverted phase contrast microscope attached to a video camera and captured using NIH imaging software (Kothakota et al., 1997; Kim and Cho, 2013b) .
FITC Annexin V-PI staining apoptosis assay
Apoptosis was determined using FITC Annexin V Apoptosis Detection Kit I based on the cell membrane changes (phosphatidylserin-based) (Satzger et al., 2010; Chang et al., 2011) . Cells were plated in 12-well culture plates at a seeding density of 4×10 5 cells/dish (5×10 5 cells/ml) and KTH-13-AMP (200 μM) was added to the culture media at a specifi ed concentration. Vehicle alone was added to the culture group serving as the untreated control. The subsequent procedures were conducted, according to the instructions provided by the manufacturer. Briefl y, after incubation for each time point, cells were harvested, washed twice with PBS and resuspended in 1X binding buffer. Annexin-V FITC and PI were applied and incubated for 15 min at room temperature (25 o C) in the dark. Fluorescence from a population of 1×10 5 cells was detected using the BD FACScan fl ow cytometer (Becton Dickinson, Mountain View, CA, USA) and CellQuest Pro (IVD) software (Becton Dickinson, Mountain View, CA, USA). The assays were done in duplicate.
Preparation of cell lysates and immunoblotting analysis
KTH-13-AMP-treated C6 glioma or MDA-MB-231 cells (5×10 5 cells/ml) were washed three times in cold PBS and then lysed in lysis buffer (20 mM Tris-HCl, pH 7.4, 2 mM EDTA, 2 mM ethyleneglycotetraacetic acid, 50 mM β-glycerophosphate, 0.1 mM sodium vanadate, 1 mM dithiothreitol, 2% Triton X-100, 10% glycerol, 2 μg/ml aprotinin, 1 μg/ml pepstatin, 2 μg/ml leupeptin, 1 mM benzimide, 1.6 mM pervanadate, 20 mM NaF and 50 μM PMSF) for 2 h on ice. The lysates were clarifi ed by centrifugation at 12,000×rpm for 10 min at 4 o C and then stored at -20 o C until used. Whole cells were then analyzed using immunoblotting (Kim et al., 2013) . Proteins were separated on 10%, 12%, or 15% SDS-polyacrylamide gels and transferred by electroblotting onto a polyvinylidenedifl uoride (PVDF) membrane. Membranes were blocked for 60 min in Tris-buffered saline containing 3% FBS, 20 mM NaF, 2 mM EDTA, and 0.2% Tween 20 at room temperature. The membranes were incubated for 60 min with specifi c primary antibodies at 4 o C, washed three times with the same buffer, and then incubated for an additional 60 min with HRP-conjugated secondary antibodies. The total, active, and phosphorylated levels of the signaling enzymes and transcription factors were visualized using an ECL system (Amersham, Little Chalfont, Buckinghamshire, UK) (Shinohara et al., 1996) .
Statistical analysis
All data presented in this paper are the mean ± standard deviation (SD) of an experiment performed with six numbers of samples. For statistical comparisons, the results were analyzed using ANOVA/Scheffe's post hoc test and KruskalWallis/Mann-Whitney tests. A p-value<0.05 was considered statistically signifi cant. All statistical tests were performed using SPSS software (SPSS Inc., Chicago, IL, USA). Similar experimental data were also obtained in an additional independent set of experiments performed with the same number of samples. 
RESULTS AND DISCUSSION
Several previous studies have shown that the Cordyceps species have anti-cancer activity (Park et al., 2009; Jayakumar et al., 2014) . It has been found that the aqueous extract of Cordyceps militaris (AECM) induces apoptosis of MDA-MB-231 cells by activation of caspases (Jin et al., 2008) . The Cordyceps pruinosa butanol fraction (Cp-BF) also has been reported to inhibit the proliferation of HeLa cells via inducing pro-apoptotic activity (Kim et al., 2010) . In addition, a recent study showed that KTH-13 isolated from Cb-BF suppressed the growth and viability, and induced apoptosis in C6 glioma cells and MDA-MB-231 cells (Kim et al., 2015) . These results imply that the structurally similar derivative from KTH-13 might also have anti-proliferative and pro-apoptotic effects. To test this hypothesis, we synthesized KTH-13-AMP and tested whether this derivative can lower the viability of several types of cancer cells including MDA-MB-231, HeLa, and C6 glioma cells.
As expected, KTH-13-AMP strongly inhibited the cell viability of MDA-MB-231, HeLa, and C6 glioma cells in a dose-dependent manner at concentrations over 100 μM (Fig. 2) . The IC 50 values of KTH-13-AMP are presented in Table 1 . Also, these results led us to further investigate the mechanism underlying the compound's anti-cancer effect.
To determine whether the anti-proliferation activity of this compound was based on apoptotic or necrotic effects, we confi rmed the morphological changes of KTH-13-AMP-treated C6 glioma cells. In previous studies, it was reported that the actin cytoskeleton was cleaved by caspases during cell apoptosis (Kim et al., 2013; Foerster et al., 2014; Kim et al., 2014) . When actin or its binding porters such as c-gelsolin and α-fodrin, regulating actin cytoskeleton, are cleaved, the truncated proteins are not able to support structural functions (Maravei et al., 1997; Martin et al., 2010) . The appearance of these truncated proteins leads to morphological changes seen in pro-apoptotic cells (Mashima et al., 1999; Utsumi et al., 2003) . As Fig. 3A shows, actin cytoskeleton-related morphological changes appeared at 150 μM from 3 h and 200 μM from 1 h. These results refl ect the differentiation and apoptosis of cancer cells. Fig. 3B depicts the time-dependent increase in Annexin V-FITC staining level from 2.05 to 25.3% between 0 and 2 h at 200 μM. C6 glioma cells stained with Annexin V-FITC demonstrated that KTH-13-AMP induces a pro-apoptotic effect in cancer cells because Annexin V-FITC is an early apoptotic marker (Vermes et al., 1995; Zhang et al., 1997) .
Next, we examined the molecular mechanism underlying the pro-apoptotic effect of KTH-13-AMP. As caspases are well known as key enzymes regulating apoptosis (Nuñez et al., 1998) , we verifi ed the effect of KTH-13-AMP on caspase-3, -8, and -9. To determine which mediates KTH-13-AMP-induced apoptosis between extrinsic and mitochondrial-dependent intrinsic pathways, patterns of total and active forms of caspase-8 and -9 were measured in KTH-13-AMP-treated C6 glioma cells. As shown in Fig. 4A , levels of both full-length caspase-8 and -9 were decreased dose-dependently, while the cleaved forms of caspase-8 and -9 were increased. These results indicate that KTH-13-AMP induces apoptosis through both extrinsic and mitochondria-dependent intrinsic pathways. In addition, the level of cleaved caspase-3, an executive caspase, was also elevated in KTH-13-AMP-exposed both C6 glioma (Fig. 4A left panel) and MDA-MB-231 (Fig. 4A right panel www.biomolther.org cells in a dose-dependent manner. Then, the ratio of Bcl-2 (an apoptosis promoter)/Bax (an apoptosis inhibitor) was observed, because the ratio between these two molecules is an important index indicating the sensitivity of cells to a death signal (Oltval et al., 1993) . KTH-13-AMP treatment reduced the Bcl-2 expression in C6 cells, but the level of Bax was consistent, resulting in a decreased Bcl-2/Bax ratio (Fig. 4B) .
Given the linkage to apoptotic activity, cell survival signaling is also associated with molecular mechanisms of the antiapoptotic pathway. For example, it has been reported that PI3K exerts its anti-apoptotic effects via various downstream targets, including STAT-3 (Zhang et al., 2005) . Therefore, we examined the effects of KTH-13-AMP on PI3K/STAT-3 signaling in C6 glioma cells. Fig. 5 shows that KTH-13-AMP strongly suppressed phosphorylation of PI3K/p85 and STAT-3 in a dose-dependent manner, although total forms of these proteins were markedly decreased at 200 μM. Also, Src phosphorylation, an upstream enzyme of PI3K, was suppressed by KTH-13-AMP without altering total forms of Src (Fig. 5) . These results indicate that KTH-13-AMP blocks the anti-apoptotic pathway by inhibiting the Src-PI3K-STAT3 signal cascade. Furthermore, it was reported that the phosphorylation of Src affects the activity of Bcl-2 and cell apoptosis through STAT-3 regulation (Kundu et al., 2014) . Thus, it is likely that inhibition of Src-PI3K-STAT3 signaling by KTH-13-AMP also induces the pro-apoptotic pathway by activating Bcl-2. However, since the causes of suppression of PI3K expression and STAT-3 expression by KTH-13-AMP (Fig. 5) remains unclear, we will now address the reason for the decreased total level of PI3K/ p85 and STAT-3 by KTH-13-AMP in terms of apoptosis.
In conclusion, we have demonstrated that KTH-13-AMP is able to suppress the cell viability of cancer cells through activation of apoptotic pathway, as summarized in Fig. 6 . The apoptotic activity of this compound was induced by activation Fig. 4 . Dose-dependent effect of KTH-13-AMP on induction of proapoptosis related proteins. (A and B) C6 glioma and MDA-MB-231 cells (5×10 6 cells/ml) treated with KTH-13-AMP for 6 h were introduced to prepare whole cell lysates and total and active form levels of caspase 3, 8, 9, Bax, Bcl-2, and β-actin were then detected by immunoblotting analysis. Relative intensity was calculated using total levels by the DNR Bio-imaging system. **p<0.01 compared to the control group. naling pathway. C6 glioma cells (5×10 6 cells/ml) were cultured with KTH-13-AMP for 6 h and whole cell lysates were prepared. The phospho-or total protein levels of STAT3, Src, and PI3K/p85 were analyzed by immunoblotting analysis. ???
